← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Revenue increased 3.6% to $726.4M, while Net income increased 107.1% to $7.0M.
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $726.4MOK
- Profitability — Net income $7.0MOK
- Cash generation — Free cash flow $136.7MOK
- Accounting — Formula-grey distress score · no manipulation flag · earnings quality safeNote
- Insiders — 0 buys; 14 sells in 365 daysNote
- Capital — share repurchases were $148.3MNote
Business
Pacira BioSciences, Inc.: Trademarks and Service Marks Pacira ® , EXPAREL ® , ZILRETTA ® , iovera ® °, the Pacira logo and other trademarks or service marks of Pacira appearing in this Annual Report are the property of Pacira, and when first used in each PART of this Annual Report, include the ® symbol.
Where the revenue comes from
Fiscal 2025, as Pacira BioSciences, Inc. reports it. History and quarterly detail are in the app.
- Net product sales$722.9M
- EXPAREL$575.1M
- ZILRETTA$116.6M
- iovera°$24.2M
- Bupivacaine liposome injectable suspension$6.9M
Leadership changes
From Pacira BioSciences, Inc.'s own filings, the day they're filed.
- Paul J. Hastings · Directors · departureeff. 2025-01-28
- Mark Froimson Frank Lee · departureeff. 2025-01-28
- Brendan Teehan · Chief Commercial Officer · appointmenteff. 2025-01-21
Latest filings
- 10-Q · Quarterly report2026-08-04
- 8-K · Company announcement2026-08-04
- 8-K · Company announcement2026-06-30
- 8-K · Company announcement2026-06-11
- 10-Q · Quarterly report2026-04-30
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Pacira BioSciences, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.